38th week of 2014 patent applcation highlights part 126 |
Patent application number | Title | Published |
20140271773 | Medical Device - The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material. | 2014-09-18 |
20140271774 | Coating For A Surface - Coatings for a surface, especially a priming coating, of the present invention have been found to be durable, resistant to oxidative degradation, erosion and depolymerisation, stable to sterilization and low particulating, and are easily applied to the required surface of a substrate in a surface-independent manner. Such coatings, when used as priming coatings to be coated with a subsequent coating, in at least some embodiments, form exterior coatings which are also highly durable and are stable to sterilisation and aging. | 2014-09-18 |
20140271775 | POROUS COMPOSITES WITH HIGH-ASPECT RATIO CRYSTALS - The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit. | 2014-09-18 |
20140271776 | Preparations Derived From Placental Materials and Methods of Making and Using Same - Preparations derived from placental materials and methods of making and using same, the preparations including a first preparation composed of placental membranes digested in collagenase, a second preparation composed of multipotent cells derived from the collagenase digested placental membranes and that are grown in adherent culture beyond confluence and a third preparation composed of ground placental membranes re-suspended in a fluid containing hyaluronic acid. The preparations can be used for regenerating damaged or defective tissue including connective tissue, nerve tissue, muscle tissue, skin tissue, cartilage tissue and bone tissue. The preparations can also be used as dermal fillers in cosmetic and plastic surgery applications. | 2014-09-18 |
20140271777 | ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING - The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms. | 2014-09-18 |
20140271778 | ENCAPSULATED KIDNEY TISSUE - Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated. | 2014-09-18 |
20140271779 | BONE GRAFT IMPLANTS CONTAINING ALLOGRAFT - Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair. | 2014-09-18 |
20140271780 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT - Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described. | 2014-09-18 |
20140271781 | HYDROGEL COMPOSITIONS WITH AN ERODIBLE BACKING MEMBER - A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed. | 2014-09-18 |
20140271782 | METHOD FOR PREPARING NANOLIPIDS WITH ENCAPSULATED ALCOHOL - A method for preparing ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. The method comprises nanolipidic vehicles in which ethanol-containing substances are encapsulated, said ethanol-containing nanolipidic vehicles can be combined with food products, desserts or beverage ingredients including those that are subsequently frozen, The food product, dessert or beverage can remain in a frozen state during consumption by an individual. A composition comprising ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. | 2014-09-18 |
20140271783 | PREFABRICATED PHARMACEUTICAL DOSAGE FORMS FROM FUNCTIONAL POLYMER FILMS - A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents. | 2014-09-18 |
20140271784 | DECELLULARIZED OMENTUM MATRIX AND USES THEREOF - Methods for defatting omentum and processes for preparing an acellular omentum, i.e., devitalized or decellularized omentum, comprising extracellular matrix for implantation into a mammalian system. Constructs for medical applications comprising decellularized omentum are also described. More specifically, mesh reinforced omentum biomatrix for soft tissue repair is described. | 2014-09-18 |
20140271785 | BIOACTIVE POROUS BONE GRAFT IMPLANTS - Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling. | 2014-09-18 |
20140271786 | BIOACTIVE POROUS BONE GRAFT COMPOSITIONS IN SYNTHETIC CONTAINMENT - Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling. | 2014-09-18 |
20140271787 | CONTINUOUS SINGLE LAYER FILM STRUCTURE INCLUDING DISCRETE DOMAINS - Disclosed herein is a soft, flexible, continuous, single-layer structural directional active delivery device such as a film product with discrete domains useful for controlled administration of the active to a patient. The discrete domains are substantially inseparable from one another, have different rates of dissolution and advantageously offer superior adhesion to the body of the patient while administering the active directionally and effectively. | 2014-09-18 |
20140271788 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2014-09-18 |
20140271789 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2014-09-18 |
20140271790 | FASCIA FIBROUS COMPOSITIONS AND METHODS FOR THEIR USE AND MANUFACTURE - Embodiments of the present invention encompass fascia, fat, and dermis fibrous compositions, and methods for their manufacture and use. In a first aspect, embodiments of the present invention encompass methods for obtaining a fascia fiber for use in producing a biotextile. Exemplary methods may include treating a cadaveric fascia tissue with acetone, and obtaining the fascia fibers from the treated fascia tissue. In some cases, methods may include processing the fascia fibers to produce the fibrous fascia biotextile. | 2014-09-18 |
20140271791 | ORAL ENERGY PRODUCTS INCLUDING ENCAPSULATED CAFFEINE - A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time. | 2014-09-18 |
20140271792 | METHYLPHENIDATE TRANSDERMAL COMPOSITIONS WITH RUBBER-BASED ADHESIVES - Transdermal compositions comprising methylphenidate in a polymer matrix comprising a rubber-based pressure-sensitive adhesive are disclosed, such as a polymer matrix comprising styrene-isoprene-styrene or polyisobutylene polymers. Method of making such compositions, and therapeutic methods using them also are disclosed. | 2014-09-18 |
20140271793 | THERAPEUTIC ELECTROSPUN FIBER COMPOSITIONS - The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits. | 2014-09-18 |
20140271794 | ANTIMICROBIAL FOAM MEDICAL PATCH AND METHOD OF MAKING THE SAME - A foam medical patch is provided including a foam substrate having integrated therein an antimicrobial material comprising a silane quaternary ammonium salt. The antimicrobial material is substantially free from arsenic, silver, tin, heavy metals and polychlorinated phenols. The silane quaternary ammonium salt includes 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. | 2014-09-18 |
20140271795 | NANOFIBROUS MATERIALS AS DRUG, PROTEIN, OR GENETIC RELEASE VEHICLES - The present invention is a bioactive, nanofibrous material construct which is manufactured using a unique electrospinning perfusion methodology. One embodiment provides a nanofibrous biocomposite material formed as a discrete textile fabric from a prepared liquid admixture of (i) a non-biodegradable durable synthetic polymer; (ii) a biologically active agent; and (iii) a liquid organic carrier. These biologically-active agents are chemical compounds which retain their recognized biological activity both before and after becoming non-permanently bound to the formed textile material; and will become subsequently released in-situ as discrete freely mobile agents from the fabric upon uptake of water from the ambient environment. | 2014-09-18 |
20140271796 | OXYBUTYNIN-CONTAINING TRANSDERMAL ABSORPTION PREPARATION - A transdermal absorption preparation containing at least one drug selected from oxybutynin and pharmaceutically acceptable salts thereof and 0.05% by mass or more of a sterol selected from cholesterols, cholesterol derivatives and cholesterol analogs, relative to a total amount of the transdermal absorption preparation. | 2014-09-18 |
20140271797 | Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Dermatological Areas of the Body - Copper ion treatments for dermatological areas of the body include solutions, creams, lotions, gels, foams, wound dressings, skin patches and suture material, each containing copper ions that bring about therapeutic effects when the copper ion treatments are applied to dermatological tissue. Methods of treating dermatological areas of the body include treatments for use on the skin and nails to treat conditions including disease, infection, inflammation, damaged or injured tissue, tissue needing to be sutured, rashes and other undesirable dermatological conditions. | 2014-09-18 |
20140271798 | Topical Copper Ion Treatments and Methods of Making Topical Copper Ion Treatments for Use in Various Anatomical Areas of the Body - A topical copper ion treatment in basic form comprises a copper ion-containing solution composed of a biocompatible solution containing copper ions obtained by leaching of the copper ions from copper metal into the solution. The copper ion-containing solution can be combined with various carriers to form various forms of the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. A method of making the copper ion-containing solution involves placing solid copper metal in a quantity of a biocompatible solution and maintaining the solution at a specified temperature for a predetermined period of time during which copper ions leach from the copper metal into the solution, and thereafter separating the solution from the solid copper metal. | 2014-09-18 |
20140271799 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 2014-09-18 |
20140271800 | IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271801 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271802 | WOUND HEALING USING TOPICAL SYSTEMS AND METHODS - The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271803 | PEPTIDE SYSTEMS AND METHODS FOR METABOLIC CONDITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271804 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271805 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES - The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271806 | MEMORY OR LEARNING USING PEPTIDE AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271807 | BRAIN AND NEURAL TREATMENTS COMPRISING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271808 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES - The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271809 | TREATMENT OF SKIN, INCLUDING AGING SKIN, TO IMPROVE APPEARANCE - The present invention generally relates to compositions and methods for transdermal delivery, treatment of skin, and improving the appearance of skin. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271810 | HAIR TREATMENT SYSTEMS AND METHODS USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for transdermal delivery, and treatment of hair related conditions. The compositions can be used in a variety of applications, including causing or promoting hair growth and/or hair pigmentation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the scalp, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2014-09-18 |
20140271812 | TREATMENT FOR CHEMOTHERAPY-INDUCED COGNITIVE IMPAIRMENT - The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound. | 2014-09-18 |
20140271813 | LIPOSOME FORMULATION AND MANUFACTURE - The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process. | 2014-09-18 |
20140271814 | CELL BINDING PEPTIDE DRUG DELIVERY SYSTEM AND COMPOUND FOR TREATING CANCER AND TUMORS - The present invention is a method and compound for treating cancer and tumors. The invention treats cancer by encapsulating certain cancer fighting drugs in a liposome. Peptides attached to the compound then guide the compound towards its target. During its journey, DSPE-PEG is used to stabilize the compound, to allow more time in the blood stream before losing effectiveness. | 2014-09-18 |
20140271815 | HEAT-AND FREEZE-STABLE VACCINES AND METHODS OF MAKING AND USING SAME - A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: Dipalmitoyl phosphatidlcholine (DPPC), Dipalmitoyl phosphatidylglycerol (DPPG), Dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen. | 2014-09-18 |
20140271816 | TREATMENT OF POTENTIAL PLATELET AGGREGATION WITH LIPOSOMALLY FORMULATED GLUTATHIONE AND CLOPIDOGREL - The composition of the invention, liposomal glutathione in combination with clopidogrel has utility for improving the efficacy of clopidogrel in preventing the aggregation of platelet that can lead to clotting. The prevention of platelet aggregation has widespread utilization in many cardiovascular conditions such as coronary artery narrowing and more consistent “antiplatelet” activity is found with the invention, the combination of clopidogrel and liposomal reduced glutathione. | 2014-09-18 |
20140271817 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF - The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein. | 2014-09-18 |
20140271818 | Targeting CLPTM1L By RNA Interference for Treatment and Prevention of Cancer - Provided herein are compositions for reducing CLPTM1L expression in a cell as well as methods for using such compositions to treat or prevent cancer in a subject. In particular, compositions comprising RNAi-inducing constructs targeted to CLPTM1L and methods of administering such compositions to a subject to treat or prevent a disease or condition associated with CLPTM1L over-expression (e.g., lung cancer) are provided herein. | 2014-09-18 |
20140271819 | ONAPRISTONE POLYMORPHIC FORMS AND METHODS OF USE - Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties. | 2014-09-18 |
20140271820 | LIPOSOME OXALIPLATIN COMPOSITIONS FOR CANCER THERAPY - The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-70 mol % of a phosphatidylcholine lipid, 25-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and oxaliplatin. Oxaliplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1. Methods for the preparation of liposomal oxaliplatin and the treatment of cancer are also disclosed. | 2014-09-18 |
20140271821 | LIPOSOMAL CISPLATIN COMPOSITIONS FOR CANCER THERAPY - The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed. | 2014-09-18 |
20140271822 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS - The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane. The PEG-lipid constitutes from about 2 to about 8 mol % of the lipids in the liposome. The taxane is docetaxel esterified at the 2′-O position with a heterocyclyl-(C | 2014-09-18 |
20140271823 | INHIBITION OF HYPOXIA-INDUCIBLE FACTOR ACTIVITY WITH CARICA PAPAYA EXTRACTS - An extract of | 2014-09-18 |
20140271824 | Acid Stable Liposomal Compositions And Methods For Producing The Same - The present invention relates to a liposomal formulation for oral delivery of a bioactive agent that considers pH stability and oxidative stability of a bioactive ingredient. These lipid formulations are superior to conventional liposomes due to their stability, thereby circumventing the need for intra-venous delivery of bioactive agents. In one embodiment, the methods and compositions of the present invention relate to the oral delivery of insulin or a prodrug thereof. | 2014-09-18 |
20140271825 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM - The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions. | 2014-09-18 |
20140271826 | KINETIN/ZEATIN TOPICAL FORMULATION - The solubility of kinetin and/or of zeatin is increased when either or both are combined in a formulation that includes a polyoxyalkylene-n-glycerol dicarboxylate component and a fatty acid component. These two components provide a synergistic increase in the solubility of kinetin and/or zeatin that is greater than that which would be expected based on the solubility of kinetin and zeatin in the individual components. | 2014-09-18 |
20140271827 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE - The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents. | 2014-09-18 |
20140271828 | Pain Reliever Composition - A pain reliever comprised of dextrose, aloe vera concentrate, and some or all of the following ingredients: propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, Dimethyl Sulfone (or Methylsulfonylmethane (MSM)), cetyl myristoleate, and, optionally, a pitcher plant extract. The resulting compositions are a water-based solution and two gel composition applied to the epidermis of mammals for relieving pain. | 2014-09-18 |
20140271829 | RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES - This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 2014-09-18 |
20140271830 | COMPOSITION AND METHOD FOR GRAY HAIR TREATMENT - A treatment for gray hair is described. The treatment can include a composition for treating gray hair with an active mixture including black trap molasses and vinegar. A standard ratio of vinegar to blackstrap molasses can be at least 1:10. The treatment can also include providing an ingestible hair treatment product including the active mixture and administering a quantity of the hair treatment product to deliver an effective amount of the active mixture. | 2014-09-18 |
20140271831 | RACECADOTRIL LIQUID COMPOSITIONS - A liquid composition comprising racecadotril and cyclodextrin. | 2014-09-18 |
20140271832 | RACECADOTRIL LIPID COMPOSITIONS - A composition comprising racecadotril, at least one surfactant and a lipid. | 2014-09-18 |
20140271833 | INJECTION-MOLDED DOSAGE FORM - An injection-molded shell of a dosage form of good quality is producible by a) providing a composition comprising i) from 25 to 90 weight percent of ethylcellulose, ii) from 7.5 to 60 weight percent of a polysaccharide or polysaccharide derivative being different from ethylcellulose, and iii) from 2.5 to 50 weight percent of at least one component being different from polysaccharides and polysaccharide derivatives, based on the total weight of the composition, with the proviso that the composition comprises zero or not more than 10 weight percent of gelatin and zero or not more than 10 weight percent of a polymer comprising homo- or copolymerized acrylic acid, homo- or copolymerized methacrylic acid, a homo- or copolymerized acrylate or a homo- or copolymerized methacrylate, and b) subjecting the composition to shearing and heat to plasticize the composition and injection-molding the plasticized composition into a three-dimensional shell of a dosage form. | 2014-09-18 |
20140271834 | Doxycycline Formulations, and Methods of Treating Rosacea - The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean C | 2014-09-18 |
20140271835 | ABUSE RESISTANT CAPSULE - The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics. | 2014-09-18 |
20140271836 | MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION - The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies. | 2014-09-18 |
20140271837 | PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM - A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin and a plasticizer; and (b) a fill that includes at least one active ingredient, polyethylene glycol, polyacrylic acid, a neutralizing agent, and water. The neutralizing agent is a primary amine or a secondary amine, and is present in an amount necessary to provide a pharmaceutical soft gelatin capsule dosage form having stable dissolution after storage. | 2014-09-18 |
20140271838 | PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM WITH MODIFIED GUAR GUM - A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage. | 2014-09-18 |
20140271839 | EXTENDED-RELEASE TOPIRAMATE CAPSULES - An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s). | 2014-09-18 |
20140271840 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2014-09-18 |
20140271841 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATIN - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and a statin and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2014-09-18 |
20140271842 | TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS - The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. | 2014-09-18 |
20140271843 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates - Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject. | 2014-09-18 |
20140271844 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS - Compositions, dietary supplement compositions, and topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases. | 2014-09-18 |
20140271845 | COATED SUBSTRATE COMPOSITIONS - Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided. | 2014-09-18 |
20140271846 | GASTRORETENTIVE DOSAGE SYSTEM AND PROCESS OF PREPARATION THEREOF - The present invention relates to novel gastroretentive dosage systems, in particular, a floating capsule which releases the drug without any lag time and which remains buoyant for a sufficient period of time in the stomach. Further, the invention relates to the process of preparation thereof. | 2014-09-18 |
20140271849 | Abuse Deterrent Solid Dosage Form for Immediate Release with Functional Score - The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system. | 2014-09-18 |
20140271850 | Controlled-Release Pharmaceutical Compositions Comprising Lamotrigine and Methods of Producing Same - Described herein is a pharmaceutical composition comprising lamotrigine as an active ingredient providing a prolonged release characteristic to allow once a day dosage regime. The composition comprises lamotrigine and a swelling agent forming a core or an extended-release composition. The core or an extended-release composition may be coated with a hydrophobic, pH-independent polymer to provide a modified extended-release composition. The formulation may comprise other pharmaceutically acceptable excipients that may act as additional release rate modifier(s), e.g., a pore forming agent in the hydrophobic polymer coat/film. Also described are the processes of preparing such dosage forms and their use. | 2014-09-18 |
20140271851 | ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS - A pharmaceutical formulation includes (1) a first dosage component comprising: a core comprising a non-ionic polymer matrix, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and an electrolyte dispersed within the matrix; a first seal coat surrounding the core, the first seal coat comprising a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein; and (2) a second dosage component comprising: a core comprising a third amount of ondansetron or an equivalent amount of an ondansetron salt thereof, at least one filler, and a lubricant; and a coating surrounding the core, the coating comprising water and a mixture of methacrylic acid-alkyl acrylate copolymers with alkaline groups. | 2014-09-18 |
20140271852 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 2014-09-18 |
20140271853 | NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS - The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease including nocturnal acid breakthrough, or the symptoms associated therewith | 2014-09-18 |
20140271855 | SOVAPREVIR TABLETS - The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein. | 2014-09-18 |
20140271856 | ORALLY DISINTEGRABLE TABLETS - An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration. | 2014-09-18 |
20140271857 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES - A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex. | 2014-09-18 |
20140271858 | COATED TABLETS OF ESZOPICLONE - Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed. | 2014-09-18 |
20140271859 | MESALAMINE PHARMACEUTICAL COMPOSITION WITH MULTIPLE DOSAGE ELEMENTS FOR REDUCED DELIVERY VARIABILITY - A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm. | 2014-09-18 |
20140271860 | Methods of Treating Colorectal Cancer - Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer. | 2014-09-18 |
20140271861 | MATRIX COMPOSITIONS FOR CONTROLLED RELEASE OF PEPTIDE AND POLYPEPTIDE MOLECULES - The present invention provides compositions for controlled release of a peptidic molecule comprising a lipid-saturated matrix comprising a biocompatible polymer and a peptidic molecule associated with PEG. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the peptidic molecule. | 2014-09-18 |
20140271862 | Rapid Disperse Dosage Form Containing Levetiracetam - A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam. | 2014-09-18 |
20140271863 | HOT WASHABLE POLY-N-ISOPROPYLACRYLAMIDE HYDROGEL DELIVERY SYSTEMS - The present disclosure is in the field of controlled release delivery of actives (e.g., drug-delivery, cosmeceutics, alternative medicine) though from an unusual and novel delivery vehicle: personal clothing. Means are disclosed for producing controlled-release systems well-suited not only for affixation to fabrics—e.g., clothing, bedding—but also for maintenance of active throughout washing cycles including hot-wash laundry cycles. Some embodiments comprise a material comprising a unique combination of the thermoresponsive polymer poly-N-isopropylacrylamide, crosslinked and water-swollen in the form of a hydrogel, with embedded thin platelet-shaped solid crystals, drug-solubilizing microparticles, and a drug or other active that is released at ambient or body temperature, but only slowly in warm or hot water. Also disclosed are particles comprising solid dispersions of active compounds dispersed in nested or layered arrangements of at least two distinct polymers, in a fiber- or rod-shaped configurations, satisfying certain mathematical criteria. | 2014-09-18 |
20140271864 | THERAPEUTIC COMPOSITIONS FOR BONE REPAIR - Individuals having diabetes are more prone to fractures, periodontitis, and other bone related issues as compared to healthy individuals. Furthermore, bone healing in diabetic patients is prolonged. The invention provides a method for decreasing bone resorption or increasing bone formation or promoting bone healing in diabetic patients. In particular, a biodegradeable polymer, such as a polyanhydride salicylate is administered at or near a bone defect site, and upon hydrolysis of the polymer will releases biologically active salicylic acid. | 2014-09-18 |
20140271866 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE - The present invention provides a transdermal drug delivery system comprising rivastigmine or its pharmaceutically acceptable salt and method of making the same. | 2014-09-18 |
20140271867 | FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided. | 2014-09-18 |
20140271868 | TREATMENT OF ACHONDROPLASIA WITH ENCAPSULATED CNP-SECRETING CELLS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 2014-09-18 |
20140271869 | HIGH DRUG LOAD BUPRENORPHINE MICROSPHERES AND METHOD OF PRODUCING SAME - A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water. | 2014-09-18 |
20140271870 | TREATMENT OF PAIN USING PROTEIN SOLUTIONS - Methods for treating pain using a protein solution comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, Compositions may also contain white blood cells and platelets. | 2014-09-18 |
20140271871 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION - The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof. | 2014-09-18 |
20140271872 | DRUG DELIVERY SYSTEM - Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients. | 2014-09-18 |
20140271873 | APPLICATION OF ENCAPSULATED CAPSAICIN AND ANALOGUES THEREOF FOR CONTROLLING CALORIE INTAKE - A zero-calorie to near-zero-calorie snacking product that, when consumed, provides a feeling of fullness prior to absorption of energy-providing food, i.e., pre-absorptive satiation is disclosed. The snacking product is based on the stimulation of vagal nerve endings in the gastro-intestinal tract by encapsulated capsaicin. The encapsulation of capsaicin avoids the burning sensation in the mouth which may be objectionable to some consumers. | 2014-09-18 |
20140271874 | STABLE CRYSTALLINE MONOHYDRATE OF EPIRUBICIN HYDROCHLORIDE AND METHOD OF PRODUCTION - The present invention relates to a stable crystalline monohydrate of epirubicin hydrochloride having water content in the range between 2.7% and 3.5% (w/w) and being devoid of residual solvents as well as to a corresponding method for its production. The method comprises: (a) adding at least a first solvent and at least a second solvent to epirubicin hydrochloride, wherein the first solvent is a linear or branched C | 2014-09-18 |
20140271875 | COMPOSITIONS INCLUDING ENCAPSULATED ISOTRETINOIN AND METHODS FOR USE THEREOF - The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne. | 2014-09-18 |
20140271876 | OPHTHALMIC FORMULATIONS - The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof. | 2014-09-18 |
20140271877 | SUBSTANTIALLY SURFACTANT-FREE, SUBMICRON DISPERSIONS OF HYDROPHOBIC AGENTS CONTAINING HIGH LEVELS OF WATER MISCIBLE SOLVENT - A composition is provided to apply to the skin, hair, or external mucosa of a human or animal, and a method for using the composition. The composition includes for example a composition for application to skin, hair or external mucosa comprising: a) dispersed submicron particles of hydrophobic agent(s) having average particle size from 100 nm to 999 nm; b) an aqueous-solvent fluid; and c) rheological modifying agent(s); wherein the aqueous-solvent fluid is 10% to 95% wt. of one or more water miscible solvent(s), 4.99% to 89.99% wt. water, and 0.01% to 10% wt. of the rheological modifying agent(s); and wherein the hydrophobic agents comprise 0.01 to 70% wt. of the skin, hair or mucosal composition; and wherein the composition is substantially surfactant-free. | 2014-09-18 |